产品
编 号：F749198
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2131089-46-6
产品详情
生物活性：
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.
体内研究：
Ontorpacept (8 mg/kg；腹腔注射，每周 3 次，共 4 周) 在 SCID 小鼠急性髓性白血病异种移植模型中具有抗肿瘤活性。Animal Model:NOD.SCID mice with AML cell transplants
Dosage:8 mg/kg
Administration:Intraperitoneal injection; 8 mg/kg, 3 times a week for 4 weeks
Result:Significantly reduced the tumor growth in bone marrow and spleen.
体外研究：
Ontorpacept (0.001-1000 nmol/L；2 h) 在急性髓性白血病，骨髓增生异常综合征，多发性骨髓瘤，B 细胞急性淋巴细胞白血病和 T 细胞急性淋巴细胞白血病患者的肿瘤细胞样本中，剂量依赖性地增加肿瘤细胞的巨噬细胞吞噬作用，平均 EC50 为 10 nmol/L。
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.
体内研究：
Ontorpacept (8 mg/kg；腹腔注射，每周 3 次，共 4 周) 在 SCID 小鼠急性髓性白血病异种移植模型中具有抗肿瘤活性。Animal Model:NOD.SCID mice with AML cell transplants
Dosage:8 mg/kg
Administration:Intraperitoneal injection; 8 mg/kg, 3 times a week for 4 weeks
Result:Significantly reduced the tumor growth in bone marrow and spleen.
体外研究：
Ontorpacept (0.001-1000 nmol/L；2 h) 在急性髓性白血病，骨髓增生异常综合征，多发性骨髓瘤，B 细胞急性淋巴细胞白血病和 T 细胞急性淋巴细胞白血病患者的肿瘤细胞样本中，剂量依赖性地增加肿瘤细胞的巨噬细胞吞噬作用，平均 EC50 为 10 nmol/L。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备